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Objectives: Patient-centered health care and shared decision making are of increasing importance in the
management of AIDS/HIV patients and require an intensive consideration of patient preferences. The present study
assesses expectations and needs of patients from the physician point of view. The aim of this study was to
compare patient and physician perspectives of relevant aspects of treatment quality such as effectiveness, quality of
life and further treatment options.
Methods: The study was performed as an anonymous survey including German physicians. Physicians treating
large numbers of AIDS/HIV patients were preferably contacted. The physicians were asked to assess their view of
patient preferences of therapy characteristics using direct measurement, as well as by means of a Discrete Choice
Experiment (DCE). The questionnaire was adopted from a previous study in which AIDS/HIV patients were asked to
assess their treatment preferences.
Results: 131 physicians completed the questionnaire, 88% of these on paper and 12% online. 70% of the
physicians were male. The mean duration since licensure was 17 years. The most frequent specialist areas were
internal medicine (N = 55), infectiology (N = 31) and general medicine (N = 27). In the direct measurement the most
relevant therapy characteristics were “drug does not affect or not affect appearance much”, “self-application of the
drug is possible” and “rarely occurring longer periods of nausea and diarrhea”. Six treatment characteristics were
selected and used to generate eight virtual pairs of therapies. To evaluate the assessments a random effect logit
model was employed. In view of the physicians avoidance of an obvious perceptibility of the disease the emotional
quality of life had by far the strongest impact on the patients’ treatment preferences as rated by physicians. With
some distance the physical quality of life with less diarrhea or nausea, as well as the possibility to participate in
social life followed on the same level.
Conclusions: Discrete Choice Experiment proved to be a valid survey technique in the evaluation of AIDS/HIV
treatment preferences as assessed by patients and by physicians assessing the view of their patients. Covering a
broad range of treatment characteristics, the physician assessments of preferences were very close to those of
AIDS/HIV patients emphasizing the high impact of quality of life, in particular the emotional quality of life on
patient preferences in the selection of treatments. Thus, the selection of particular treatment options should be
accompanied by a deliberate consideration of treatment features, which need to be considered in order to
maximize patient adherence and compliance.
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The acquired immune deficiency syndrome (AIDS) is a
disease with failure of the immune system caused by the
human immune deficiency virus (HIV). It is characterized
by certain life-threatening opportunistic infections and ma-
lignancies. Progression to AIDS can be delayed by com-
bined antiretroviral therapy (cART, [1]). HIV-infection
occurs by mucosal or parenteral body fluid contact, i.e.
blood, semen, vaginal fluid, pre-ejaculate, and breast milk
[2]. AIDS was first reported in 1981 [3]. At the end of
2011, an estimated 34 million people were living with HIV
worldwide. Hence, HIV infection in humans is classified as
pandemic by the World Health Organization [2]. The
number of people dying of AIDS-related causes dropped
to 1.8 million in 2010, down from a peak of 2.2 million in
the mid-2000s. In 2011 there were 2.5 million new HIV in-
fections. This was 20% less than in 2001. According to
UNAIDS data Germany has an estimated HIV prevalence
of 0.1. In 2011 approximately 73,000 Germans were living
with HIV/AIDS [4].
The availability of cART that reduces both the mortality
and morbidity associated with HIV infection is one of the
main factors influencing this decrease [2]. In addition the
effective reduction of viral load through cART substantially
reduces the risk of HIV transmission [5]. HIV viral suppres-
sion, reduced rates of resistance, an increase in survival,
and improved quality of life have shown to be strongly
correlated with adherence to antiretroviral therapy [6,7].
Besides quality of life the dosing is being discussed as
patient-relevant. Because HIV treatment is a lifelong en-
deavor, and because many patients will initiate therapy
when they are generally in good health without obvious
signs or symptoms of HIV disease, adherence poses a spe-
cial challenge depending on the side-effects and requires
commitment from the patient and the health care team [8].
Understanding about patient preferences characterized
through expectations and needs concerning therapeutic
options is an important prerequisite to understand patient
adherence. Research on this topic is of increasing interest
and supplements evidence-based results on efficacy and
tolerability. As an important part of benefit-risk assess-
ments the evaluation of patient preferences is recom-
mended by the American FDA [9], as well as by the
German institutions G-BA (Federal Joint Committee) [10]
and IQWIG (Institute for Quality and Efficiency in Health
Care), which explicitly encourage the integration of
conjoint analyses of patient preferences [11].
In a previous study [12] we evaluated therapy-related ex-
pectations and needs of AIDS/HIV-patients using direct
measurement, as well as by means of a Discrete Choice Ex-
periment (DCE). 218 patients completed this study. In the
direct measurement the most relevant therapy characteris-
tics were “Self-application of the drug (at home or on-
the-go) possible”, “Drug has very high efficacy (reduction ofviral load)” and “Long term (hidden) side-effects (e.g. organ
damage) is unlikely”. Based on these data eight hypothetical
therapy scenarios were generated and used in a Discrete
Choice Experiment. The main result was the high impact
of quality of life, in particular the emotional quality of life
on patient preferences on the selection of treatments.
The present study assesses expectations and needs of
AIDS/HIV-patients from the physician point of view,
however, not reflecting their own preferences, but their
view of patient preferences. The aim of this study was to
assess physicians’ judgments of relevant aspects of treat-
ment quality such as effectiveness, quality of life and fur-
ther treatment options. In a second step these results
should be compared to the findings on patient prefer-
ences. This objective gets even more important on the
background of increased patient-centered healthcare and
the postulation of shared decision making among health
professionals and patients. For that reason an understand-
ing of the concordance of physicians and patients is abso-
lutely essential. The study procedure has already been
established in the therapy of multiple myeloma [13], where
some congruency between patient and physician assess-
ments was found, although physician and patient commu-
nication has been shown to be critical to determine the
best treatment options regarding patient preferences.Methods
The study was performed as an anonymous survey includ-
ing German physicians. Data were collected from October
until November 2010 using either online or paper ques-
tionnaires. The physicians were contacted either in writing
and were given the paper-based questionnaire version with
stamped addressed envelopes, or via email/internet. Both
methods were offered since older physicians may not have
wanted to use the online version. In terms of content, there
were no differences between both versions of the question-
naire. In recent studies both methods of administration
have proven to be highly reliable and comparable [14].
The recruitment of physicians was performed using a
nationwide database from Janssen-Cilag GmbH attended
for informational and marketing purposes. From this data-
base those physicians were selected who were known for
treating large numbers of AIDS/HIV patients, because it
was expected that these physicians are very experienced
concerning patient preferences. A total of N = 404 physi-
cians were contacted. Both paper-based questionnaires and
the link to the online version were sent to the selected phy-
sicians. No personal data such as addresses, names or
phone numbers were collected. It was intended to get a re-
turn of 100 evaluable questionnaires as this number would
be sufficient for DCE-estimates according to the formula
for sample size calculation by Johnson and Orme [15].
Moreover a sample size of N = 100 would have been
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tioners, venereologists, internists) in Germany.
The questionnaire encompassed the following sections:
○ Section A (physician characteristics): socio-
demographic parameters of physicians: gender, num-
ber of years in the profession, specialization, self-
assessment of knowledge about patient preferences.
○ Section B (practice characteristics): Frequency of
AIDS/HIV patients in practice, frequencies of
treated and untreated patients, frequencies of
patients being experienced or naïve about treatment.
○ Section C: Direct assessment of importance of 26
items on AIDS/HIV therapy characteristics (Five-point
Likert scale).
○ Section D: Discrete Choice Experiment (DCE) for
patient preferences from the physician point of view
using eight pairs with six characteristics each.
The 26 items on AIDS/HIV therapy characteristics of
section C (shown in Table 1) and the eight pairs of treat-
ment comparisons of section D were adopted from a previ-
ous study [12] in which AIDS/HIV patients were asked to
assess their treatment preferences. In this study, treatment
characteristics had been developed using a qualitative pre-
study. Furthermore, summarizing aspects of importance of
treatment characteristics had been identified by factor ana-
lysis and pair comparisons for the Discrete Choice Experi-
ment had been generated by an orthogonal experimental
design [12].
Ethical considerations: The study is a social science
survey and does not contain personal data (completely
anonymous survey), surgeries (tests, experiments, and
medication), biomedical research or additional data, as
in many epidemiological investigations. Therefore an
ethic vote in Germany was not necessary. All respon-
dents were informed about the study and its potential
risks and benefits prior the participation. Respondents
had to sign an informed consent. They participated vol-
untarily and the participant could stop at any time. The
study with all information material and the survey in-
strument was approved by the Janssen-Cilag GmbH.
Conjoint analysis and Discrete Choice Experiment (DCE)
The Discrete Choice Experiment is a choice based
method, and a variant of the conjoint analysis that was
made possible through the theoretical work of Lancaster
[16] and McFadden [17]. In the Discrete Choice Experi-
ment different therapies are presented pair-wise and the
subjects have to decide for one of the options [18]. In a
first step all characteristics that are relevant for each
target group have to be identified [19].
The treatment alternatives are presented to the subject
and the subject has to decide for one of the presentedoptions. Based on the decision behavior the relevance of
the different characteristics for the decision can be cal-
culated and described by coefficients. The calculation of
coefficients is performed via the maximum likelihood
method. According to the underlying distribution func-
tion different estimation methods are applied. In most
cases these are probit or logit estimations [20-22].
To appreciate the importance of possible statistical
correlations between main effects and interactions, the
number of combinations was reduced to a more manage-
able size without losing essential information through an
orthogonal design (when making certain assumptions
about interaction effects). The SPEED software package
was used to select the optimal subset of scenarios [23],
maximum dissimilarity between therapy alternatives was
achieved by generating the alternative B as exact mirror
image of alternative A (using the fold-over technique) [12].
In this study we conducted the DCE technique with eight
pair decisions, each with six characteristics. Respondents
had to choose eight times between treatment A or B. The
presented treatment pairs, as well as the characteristics
were the same as in the previous patient study with verbal
adaptions to physicians. Linguistically, the questions were
adapted in the questionnaire for physicians from a
self-assessment: “What would you choose …?” into a judg-
ment: “How do you think your patients would rate” and
“What would your patient choose?”.Statistical analysis
For statistical data analysis we used analysis of variance, re-
gression analysis, factor analysis, and random effect logit
models for the DCE. All statistical analyses were done
using SPSS and STATA. A p-value <0.05 (two sided) was
considered as being statistically significant.
Direct assessments of the importance of therapy charac-
teristics were evaluated for effects of socio-demographic
baseline characteristics of the physicians using analyses of
variance. However, the problem of multiple testing has to
be borne in mind: with more than 200 statistical tests to be
performed some significant results will be produced “by
chance”, they are however artefacts (approx. 10 of such
results must be expected at a 95% confidence level). A pos-
sible increase of significance level (e.g. Bonferroni correction)
may minimize these errors but increases the risk of ignoring
really existing relationships. Therefore, a significance level of
p < 0.05 was used.Results
Physician characteristics
Between October and November 2010, N = 131 physicians
completed the questionnaire. Most of the physicians (88%)
answered via paper version and 12% online. 70% of the
physicians were male.
Table 1 Mean importance of therapy characteristics assessed by physicians taking the view of their patients and by
the patients themselves
Mean importance
Physicians1 Patients2 Therapy characteristic
Benefits
85 89 Drug improves physical state (e.g. better mobility, pain relief)
84 94 Drug has very high efficacy (reduction of viral load)
83 90 Drug promises maximum prolongation of life expectancy
77 81 Drug improves emotional and mental state (e.g. less thoughts about disease)
76 82 Drug allows for improved mobility (e.g. longer journeys possible)
76 78 Drug improves social contact opportunities (e.g. visits possible)
73 85 Long duration of efficacy following application
62 88 Drug allows further therapy options (in the future)
60 90 Drug does not generate resistance
Side effects
92 89 Drug does not or does not affect appearance much (disease not visible, e.g. by fat redistribution)
87 86 Rarely occurring longer periods of nausea due to drug application
87 86 Rarely occurring longer periods of diarrhea due to drug application
79 92 Long term (hidden) side-effects (e.g. organ damage) is unlikely
57 30 Pregnancy is allowed during treatment period
56 80 Drug can be used also in case of comorbidities
Mode of administration
90 94 Self-application of the drug (at home or on-the-go) is possible
86 82 Flexible application during course of the day (e.g. delay of 1 hour is possible)
86 79 Simple application: only few tablets
83 85 Drug can be taken along without problems (transportation)
81 73 Inconspicuous drug intake (discreet, unnoticed by environment)
77 73 Drug has to be taken only once daily
76 84 Long term use of the drug is possible
69 75 Drug does not cause additional costs for patient (no extra payment)
68 71 Treatment does not require much time (waiting time, time for treatment)
47 51 Therapy-free intervals/treatment breaks are possible
35 60 Dosing of drug may vary according to current health state
1Results of the present study, 2Results of the previous study [12], bold: attribute used in DCE.
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sional experience. 33% of the physicians were practicing
for 20 years or more, 46% for 10 to 20 years and 21% had a
professional experience of less than 10 years. The mean
duration of licensure was 17 years (1993). 82% of the physi-
cians were specialists in at least one field with a maximum
of five fields. The most frequently mentioned specialties
were internal medicine (N = 55), infectiology (N= 31) and
general medicine (N = 27).
A summary of physician characteristics is shown in
Table 2.
34% of the physicians claimed to have “very good”
knowledge about patient preferences; 60% rated their
level of knowledge as “good”. A total of 5% thought theyhad a “medium” level of knowledge about preferences,
whereas 1% claimed it was “not so good”.
Practice characteristics
As the questionnaires were sent preferably to physicians
known for large patient numbers, 85% of the physicians
documented that they had treated 50 AIDS/HIV patients
or more during the last 12 months. 8% had treated 25–49
patients, 3% had treated 10–24 patients and 3% had treated
1–9 patients. A small proportion of physicians (1.5%) had
not treated or counseled any AIDS/HIV patients in the
previous 12-month period.
66% of the physicians documented that at least 75% of
their AIDS/HIV patients received antiretroviral treatment
Table 2 Physician characteristics, professional experience











1990 or earlier 33%
1991-1999 46%
2000 or later 21%




Not so good 1%
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50-74%, 25-49% and 0-24% of their AIDS/HIV patients re-
ceived antiretroviral treatment, respectively.
Direct assessment of AIDS therapy characteristics
Specific characteristics that patients consider relevant
in the assessment of antiretroviral treatments were col-
lected on the basis of the previous study [12]. The phy-
sicians had to rate the importance of 26 therapy
characteristics from their patients’ point of view using
a Five-point Likert scale, ranging from “very important”
to “not important”. Specific point values of 0 (“not import-
ant”) to 100 (“very important”) were equally attached to
the five Likert categories. The mean assessments of im-
portance are shown in Table 1, which also contains the
patient assessments resulting from the previous study [12].
Most of the items concerning quality of treatment are
believed to be of relatively high mean importance
(>70 points) for the patients as assessed by the physi-
cians. These ceiling effects are not surprising, since only
aspects were presented, that were rated as important ac-
cording to the literature and the qualitative pre-study
during the previous patient preference study.
Influence of socio-demographic characteristics of
physicians
Using analyses of variance, the assessments were evalu-
ated for effects of socio-demographic baseline character-
istics of the physicians. The results showed in particular
that physicians with more professional experience andphysicians with a higher number of treated patients
assessed some characteristics as more important than
the other physicians:
– Physicians with more professional experience
assessed three items as significantly more important:
“Drug has very high efficacy”, “Drug does not
generate resistance”, “Long term side-effects are
unlikely”.
– Physicians with large patient numbers assessed six
items as significantly more important:
“Inconspicuous drug intake”, “Rarely occurring
longer periods of diarrhea”, “Long term side-effects
are unlikely”, “Drug improves physical state”, “Drug
does not affect or does not affect appearance much”
as well as “Drug improves emotional and mental
state”.
Differences between physician and patient assessments
In the previous study asking patients as well as in the
present study asking physicians the same 26 items were
used to assess the relevance of treatment characteristics
from the view of the patients, thus allowing a compari-
son between the assessments of patients and physicians.
In most of the aspects the assessments of the physicians
were close to those of the patients – the differences be-
tween both mean values were mostly below 10 points.
This indicates that physicians had a good feeling for the
desires and needs of the patients in most of the aspects.
Differences were found for the item “Pregnancy is pos-
sible”, which was assessed as much more important by
physicians as compared to patients; however, this item
was not particularly important in both groups, which
implicates that the different assessments of relevance are
both in the lower range of importance. When comparing
both data sets it becomes obvious that physicians made
clearly lower relevance assessments on four aspects than
the patients did. These were the items “Further treat-
ment options possible”, “No resistances generated”,
“Drug can be used also in case of comorbidities” and
“Dosing may vary according to current health state”.
Obviously, the physicians underestimated the relevance
of these aspects as assessed by the patients. Interestingly,
these differences between physicians and patients were
only found in aspects that were not different in sub-
groups of physicians, implicating that the misinterpreta-
tions of patient assessments occurred with all physicians,
not only with some of them.
Preferences in the Discrete Choice Experiment
Discrete Choice Experiments (DCE) are limited to the
use of only a few characteristics. Based on the previous
study on patient preferences [12] using the same 26
therapy characteristics and a following principal
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six characteristics were selected and described by a posi-
tive and a negative pole (see Table 3).
Generation of pairs
Based on the six therapy characteristics eight virtual
therapies were generated. These eight therapies were
presented to the patients in eight pairs from which the
patient had to select one of the two therapies (A or B).
In total, 1047 valid assessments were available from
131 physicians. As each physician had to make 8 assess-
ments, only one assessment was missing.
A random effect logit model was created, which takes
the partial dependency of observations from the same
person concerning the parameter estimation into ac-
count. Estimated coefficients and their standard errors
are shown in Table 4.
In this model significant (non-zero) estimations for the
positive poles were demonstrated for all six characteris-
tics indicating the expected direction: the positive pole
was chosen significantly more frequent than the negative
one. Thus, all six parameters are statistically significant
predictors of treatment preferences.
As shown in Table 4, the patient treatment preferences
assessed by the physicians depend on the six characteris-
tics to a different degree. From the physicians point of
view avoidance of an obvious perceptibility of the disease
(“Emotional quality of life”; characteristic 5) had by far
the strongest impact on the patient treatment prefer-
ences. With some distance the “Physical quality of life”
(characteristic 4) with less diarrhea or nausea, as well as
the “Possibility to participate in social life” (characteristic
6) followed on the same level. With a clear distance but
on the same level “Maximum increased life expectancy”
(characteristic 1) and “Avoidance of long-term side-
effects” (characteristic 2) followed. In the view of the
physicians the “Flexibility of dosing”, represented by an
intake of a maximum of 3 tablets per day (characteristic
3) had the lowest but still statistically significant impact.
Differences between the attribute “Emotional quality
of life” (characteristic 5) and each of the other five
characteristics were statistically significant at least on a
p < 0.05 level. Thus, the relevance of this treatment char-
acteristic for treatment preferences is significantly higherTable 3 Treatment characteristics for Discrete Choice experim
Characteristics Positive pole (+)
Life expectancy Maximal increase
Long term side-effects Improbable (<20% of pa
Flexibility of dosing Max. 3 tablets/day
Physical quality of life Diarrhea, nausea less fre
Emotional quality of life Disease not obvious for
Social quality of life Participation in social lifethan that of every other characteristic. The characteris-
tics “Physical quality of life” and “Social quality of life”
were not significantly different in relevance on treatment
preferences. However, both were significantly different
from each of the other four characteristics: both were
less relevant than characteristic 5, but more relevant
than each of the characteristics 1, 2 and 3. No significant
differences were found between characteristics 1, 2 and
3, but each of them is less relevant on treatment prefer-
ences than the characteristics 4, 5 and 6.
A supplementary partial log likelihood analysis as pro-
posed by Lancsar et al. [24] yielded a similar hierarchy
as the interpretation based on the item coefficients.
In additional interaction analyses, subgroup effects
were found on a bivariate level for the characteristics
“Maximum increased life expectancy”, “Avoidance of
long-term side-effects”, “Physical quality of life” as well
as “Emotional quality of life”. Using a simplified multi-
variate model, including only significant subgroup effects
in addition to main effects, three effects were found:
 Physicians without specialization assessed the
relevance of “Maximum increase of life expectancy”
(characteristic 1) higher than their colleagues with
specialization.
 In contrast, they assessed the relevance of
“Emotional quality of life” (characteristic 5) lower
than their colleagues with specializations.
 Physicians who documented having a very good
knowledge of patient preferences assessed a low
relevance for “Long-term side-effects improbable”
(characteristic 2).
Differences between physician and patient preferences
The Discrete Choice Experiment assessments of this
study present the physician view about what they think
the preferences of patients are.
The total set of treatment comparisons including
physician and patient preferences was adopted from
Mühlbacher et al. [12]. Both physician and patient pref-
erences correspond to a high degree. They show rather
clear decisions in five of the eight pairs, whereas in three
pairs the less frequently chosen alternative was selected
in at least 22% of the assessments.ent
Negative pole (−)
Moderate increase
tients) Possible (≥20% of patients)
≥4 tablets/day
quent Diarrhea, nausea more frequent
others Disease obvious for others
possible Participation in social life restricted
Table 4 Results of random effect logit model (Discrete Choice Experiment; negative pole as reference group)
Characteristics Coefficient SE Sig. Partial log
(coeff.) likelihood
Life expectancy: maximum increased 0.846 0.265 ** −373.0
Long term side-effects improbable (<20%) 0.831 0.224 *** −374.5
Flexibility of dosing: max. 3 tablets/day 0.635 0.261 * −370.3
Physical quality of life: diarrhea, nausea less frequent 1.925 0.256 *** −402.7
Emotional quality of life: disease not obvious for others 4.003 0.269 *** −604.8
Social quality of life: participation in social life possible 1.947 0.269 *** −402.1
Model constant −5.316 0.417 ***
***p < 0.001, **p < 0.01, *p < 0.05.
Model parameters:
LR Chi2 (df = 6) = 715.90.
Log likelihood = −367.7.
Prob > Chi2 = 0.0000 (i.e. p < 0.001, ***).
% correctly classified = 85.0%.
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selves had been collected in a previous study [12] using
the same study material. The DCE results of both stud-
ies are presented in Figure 1, while Table 5 displays the
results of random effects logit models for both groups.
Respondents’ choices are made conditional upon the
levels presented in the choice set. Choices inform about re-
spondents perceived (expected) utility of each alternative
within the choice scenarios. The mean relative importance
of the attributes can be interpreted as the difference
between the upper and the lower level.
As the mean relative importance is measured on an
arbitrary scale, we have normalized the most important at-
tribute (highest coefficient as illustrated in Table 5) as 10
units and measured the other attributes’ importance rela-
tive to this change (illustrated in Figure 1). Instead ofFigure 1 Coefficients of Discrete Choice Experiment (positive pole) fo
previous study, [12]) (normalization of coefficients).analyzing mean relative importance, trade-offs between
changes in time or cost can be explicitly mapped. Measur-
ing people’s willingness to make trade-offs is consistent
with welfare economics. It can be measured by determin-
ing the disutility which is generated through a change
from the most preferred level to the least preferred level
and by identifying the corresponding increase in healthy
life years, or decrease in cost that is needed to return to
the original level of utility. Since we did not include cost
or time, we were not able to estimate money equivalents
or healthy-years equivalents.
Two aspects are particularly striking:
 The ranking order of the six characteristics is nearly
identical for both groups. By far most important is
the characteristic “Emotional quality of life”,r physicians (data of present study) and patients (data of















Life expectancy: maximal increase 0.735 0.152 *** −717.7 0.846 0.265 ** −373.0
Long term side effects improbable (<20%) 0.408 0.147 ** −709.5 0.831 0.224 *** −374.5
Flexibility of dosing: max. 3 tablets/day 0.454 0.151 ** −710.1 0.635 0.261 * −370.3
Physical quality of life: diarrhoea, nausea less
frequent
1.611 0.152 *** −769.4 1.925 0.256 *** −402.7
Emotional quality of life: disease not obvious
for others
2.984 0.153 *** −981.7 4.003 0.269 *** −604.8
Social quality of life: participation in social life
possible
1.140 0.153 *** −735.4 1.947 0.269 *** −402.1
Model constant −3.726 0.214 *** −5.316 0.417 ***
1) ***p < 0.001, **p < 0.01, Model parameters: Wald Chi2 (df = 6) = 470.81, Log likelihood = −705.7, Prob > Chi2 = 0.0000 (i.e. p < 0.001, ***), Prob ≥ Chi2 = 1.000.
2) ***p < 0.001, **p < 0.01, *p < 0.05; Model parameters: LR Chi2 (df = 6) = 715.90, Log likelihood = −367.7, Prob > Chi2 = 0.0000 (i.e. p < 0.001, ***),
% correctly classified = 85.0%.
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quality of life” (on the same level in physicians; with
some difference in patients) and the characteristics
“Maximum increased life expectancy”, “Long-term
side-effects improbable” and “Flexibility of dosing”
follow on rank 4 to 6.
 The most important differences between both
groups are:
○ a) Patients assessed the characteristic “Less
diarrhea/nausea” higher than “Participating in
social activities is possible” and
○ b) Patients assessed the “Maximum increase of
life expectancy” somewhat lower than physicians
whereas physicians assessed the “Avoidance of
long-term side-effects” much higher than patients
themselves.
At the end of the questionnaire, the physicians were asked
to give an explicit additional assessment of the degree of
difficulty they had in performing the paired comparisons in
the DCE. 2% assessed the ratings as “very difficult”, 26% said
it was “rather difficult”, 43% gave a medium ranking (“some
comparisons more difficult than others”), 24% thought it was
“not very difficult” and 5% claimed they had “no problems
at all” in completing the DCE. This means that the DCE can
be considered as feasible from the physician point of view.
Discussion
Patient opinions and desires concerning medical services
(e.g. medication, therapy modalities) are often not suffi-
ciently considered. However, taking into account concepts
like “patient involvement” and “shared decision making”,
an understanding of patient priorities concerning treat-
ment decision making is required. Furthermore, it is
important to evaluate whether the attending physicianssufficiently know the preferences of their patients to
consider them adequately in (mutual) treatment decisions.
In a previous study (N = 218), we analyzed patient
preferences in the treatment of AIDS/HIV using direct
assessments and a Discrete Choice Experiment [12]. The
study presented here used the same assessments for a
survey among physicians (N = 131), however, asking not
about their own preferences, but about their view of pa-
tient preferences. Subsequently, a Discrete Choice Ex-
periment was used to determine the degree to which
each therapy characteristic influenced the decisions.
The survey was offered paper-based and as online
questionnaire. The intense usage of the paper version
was probably due to the recruitment procedure, which
included sending off the paper-based questionnaire. As
the recruitment concentrated on physicians known for
large numbers of AIDS/HIV patients, the study results
can be seen as being representative only for this group
of physicians. However, it was supposed that physicians
experienced with treating a large proportion of HIV/
AIDS-patient are also knowledgeable to patient needs
and priorities. The best, albeit most demanding, ap-
proach would be to ask physicians and their (real)
patients at the same time. However, this was not possible
within the scope of this study. In order to achieve highest
possible comparability we recruited highly experienced
physicians that treat a large number of HIV/AIDS patients.
Moreover, HIV/AIDS patients are highly active and well
organized in terms of self-help groups. They are highly in-
formed and often have long-term relationships with their
physicians, which enables shared-decision making as well
as a good judgment by physicians.
For the direct assessment of preferences physicians had
to assess 26 treatment characteristics which had been
found to be relevant in the previous study [12] based on
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pected, a ceiling effect was found with ratings in the upper
range of the scales for many of the characteristics. This
might be due to the fact that, resulting from the qualita-
tive pre-study, mainly important characteristics were pre-
sented. Within the rating, the top of the priority list is
marked by preferences such as “drug does not affect or
does not much affect appearance”, “self-application is
possible”, but also by avoidance of side effects.
In most of the treatment characteristics the assessments
of physicians seen in this study and patients found in the
previous study [12] are congruent. In some characteristics,
however, there are obvious differences: thus, compared to
patient assessments, physicians tend to underestimate the
relevance of the characteristics “Drug allows further ther-
apy options in the future”, “Drug does not generate resist-
ance”, “Drug can be used also in case of comorbidities”
and “Dosing of drug may vary to current state”. Effects of
socio-demographic baseline characteristics of the physi-
cians showed that professionally more experienced physi-
cians assessed “High efficacy”, “Not generating resistance”
and “Unlikely long term side-effects” as being more im-
portant, while physicians with large numbers of patients
for example assessed “Unlikely long term side-effects”,
“Improvement of physical state” and of “Emotional and
mental state” as more important. Whereas these assess-
ments of more experienced physicians seem to be closer
to the patient preferences, the assessments of less experi-
enced physicians might truly reflect a different patient
population. However, these findings can also be a misinter-
pretation of patient preferences due to less patient contacts.
In a second step, preferences were measured using a
Discrete Choice Experiment in which the physicians had
to choose eight times between two treatment options,
which were described by combinations of 6 quality as-
pects. The influence of each treatment characteristic on
the treatment decision was evaluated.
The clearly highest relevance for the treatment selec-
tion of physicians as well as patients was found for
emotional quality of life indicated by the fact that the
disease was not obvious for other persons. From the pa-
tient point of view the avoidance of physical impair-
ments such as diarrhea and nausea followed next, and
with some distance the possibility of participating in so-
cial life – physicians assessed both of these aspects at
the same level.
As well as in the previous study on patient assess-
ments of treatment preferences, the DCE results of the
current study correspond partly to the direct measure-
ment of needs where emotional, physical and social
quality of life were also in the upper range of prefer-
ences. Again the characteristics “Maximum increase of
life expectancy” and “Avoidance of the risk of long term
side-effects” seem to be far less important in DCE thanin the direct assessment. This might be due to the fact
that the direct assessment using ratings has certain ceil-
ing effects, resulting in all attributes being important.
On the contrary the DCE focusses on trade-offs between
the attributes. This might result in lower assessments.
As the DCE results show particularly those aspects are
weighted high that emphasize HIV/AIDS more as a
chronic disease than as directly life threatening condi-
tion. As a consequence, therapy adherence of the pa-
tients may be increased by better focusing on quality of
life arguments than efficacy and safety aspects. However,
these arguments differ from results shown in other stud-
ies like pill count, dosing frequency and adverse events
as shown by Stone et al. [25] or resistance, regimen con-
venience and sleep disturbance shown by Beusterien
et al. [26].
Compared to patients’ preferences concerning the
therapy of multiple myeloma [12], the results of the
present study demonstrate preference ratings, which
may be more affected by the chronic aspect of the dis-
ease, whereas preferences of multiple myeloma patients
seem to be more affected by the progressive character of
their disease leading to increase of life expectancy and
possibility of further treatment options as most import-
ant factors. Interestingly, in the present study physician
assessments of patient preferences were somewhat closer
to patient assessments than in multiple myeloma pa-
tients. Maybe the preferred recruitment of more experi-
enced physicians in the present study has had an
influence and possibly indicates the importance and the
need to communicate patient preferences at least to less
experienced physicians.
The current study has shown that the preferences of
patients and physicians assessing their impression on pa-
tients’ preferences were mostly concordant. However, as
various studies and a recent review on the concordance
of patients and physicians have shown patient prefer-
ences and expert judgments can differ [27] and that the
results should always be interpreted in the light of actual
circumstances given in a study [28].
Some limitations of the current study are to be discussed.
Because the DCE is only manageable using a limited num-
ber of characteristics and pairs to be compared, decisions
were made during the composition of characteristics
reflecting the factor structure found in the direct assess-
ment and the construction of comparisons [12]. Doing this,
however, some problems remained: dosing aspects were
presented as maximum 3 tablets per day versus more,
whereas the direct preference measurement revealed more
facets of application such as dosing according to current
health status, treatment free periods or self-application. As
these and some more aspects of application affected at
least two factors in the factor analysis, the characteristic
“dosing flexibility” may have been defined too simple to
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more, the definition of poles of the characteristics may
have influenced the preference decisions: the item “in-
crease of life expectancy” was presented as “increase” ver-
sus “maximum increase”. Maybe the perceived difference
between these two poles was too small to prefer this char-
acteristic against others. Thus, the somewhat surprising
low importance of this efficacy parameter may be the con-
sequence of too close definitions of the poles of this
characteristic.
Another limitation arises from the two different samples
assed for the comparison. The patient recruitment was
performed by the German Competence Network for HIV/
AIDS, while the recruitment of physicians was performed
using a nationwide database from Janssen-Cilag GmbH.
Hence the patients in the previous study are maybe dis-
similar from those treated by the doctors in this study.
Moreover physicians may have based their assessments on
thousands of their patients. These patients might not be
similar to the 218 patients in the patient sample.
Conclusion
In summary, direct preference assessments as well as
DCE contribute important findings to the knowledge of
AIDS/HIV treatment preferences. On the one hand,
these findings cover assessments of patients suffering
from AIDS/HIV, which were shown in a previous study
[12] as well as the physician judgments. The main result
of both studies was the fact that AIDS/HIV-patients as
well physicians are congruent in their assessments.
There is concordance of both groups that it is very im-
portant that an antiretroviral therapy supports the pa-
tients’ quality of life, in particular the emotional quality
of life. This perhaps reflects a paradigm shift in prefer-
ences, since more convenient and less toxic options for
cART became available within the last decade.
On the other hand, the understanding of physicians
about the patient preferences is important as the selection
of a particular treatment regimen should be accompanied
by a conscious consideration of features of possible treat-
ment options, which need to be considered in order to
maximize patient adherence and compliance to the
selected treatment. The results of the current study have
shown that the preference assessments of patients them-
selves and physicians assessing their impression how
patients would assess preferences were predominantly in
clear concordance. This means that the participating phy-
sicians have a good knowledge of the treatment prefer-
ences of patients – at least if they are treating or
consulting large numbers of AIDS/HIV patients.
This study was based on the presumption: If health-
care services available are tailored to the needs of the
target group, it is assumed that the motivation to utilize
those services and participate actively in therapy measurescan be increased and long-term treatment success im-
proved. The results on treatment preferences demonstrate
that the combined use of a direct assessment for rating
different levels of importance on one hand and a collec-
tion of data by a DCE on the other is reasonable and
effective. Both procedures yield comparable results,
with the direct assessment being able to cover a greater
number of aspects and the DCE focusing on six of the
most important aspects.
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